-
1 Comment
Chongqing Lummy Pharmaceutical Co., Ltd is currently in a long term uptrend where the price is trading 1.3% above its 200 day moving average.
From a valuation standpoint, the stock is 69.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.9.
Chongqing Lummy Pharmaceutical Co., Ltd's total revenue sank by 8.6% to $512M since the same quarter in the previous year.
Its net income has dropped by 41.5% to $-327M since the same quarter in the previous year.
Finally, its free cash flow fell by 109.1% to $-8M since the same quarter in the previous year.
Based on the above factors, Chongqing Lummy Pharmaceutical Co., Ltd gets an overall score of 2/5.
| Sector | Healthcare |
|---|---|
| Industry | Drug Manufacturers - General |
| Exchange | SHE |
| CurrencyCode | CNY |
| ISIN | CNE100000H10 |
| Beta | 0.6 |
|---|---|
| Market Cap | 3B |
| PE Ratio | None |
| Target Price | 10.78 |
| Dividend Yield | None |
Chongqing Lummy Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in China. The company provides anti-tumor, anti-inflammatory, antibacterial, digestive, anti-virus, blood system, cardiovascular system, acid-base balance nutritional medicine, endocrine system drugs, tumor adjuvant medication, antifungal, and opioid receptor antagonists. Chongqing Lummy Pharmaceutical Co., Ltd. was founded in 1999 and is headquartered in Chongqing, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 300006.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
